A huge purchase at a biopharmaceutical company ramped up slow insider buying in the new year. Activist investor Carl Icahn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback